By admin 
CureSearch for Children’s Cancer, a leading national non-profit dedicated to accelerating the development of transformative pediatric cancer treatments, has officially announced the appointment of Osama Alsaleh to its Board of Directors. This strategic addition to the organization’s leadership comes at a pivotal moment in the pediatric oncology landscape, as the industry increasingly looks toward venture capital models, technological integration, and cross-sector partnerships to bridge the funding gap that often hinders the progress of life-saving therapies for children. Mr. Alsaleh, a distinguished executive with an extensive background in healthcare innovation and strategic investment, currently serves as the Head of Partnerships at Plug and Play Health. His appointment is expected to bolster CureSearch’s ability to navigate the complex intersection of biotechnology, global health equity, and private sector investment, ensuring that promising research transitions more efficiently from the laboratory setting to the clinical environment.
A Career Defined by Innovation and Global Health Strategy
Osama Alsaleh joins the CureSearch Board of Directors with a professional trajectory that reflects a deep commitment to systemic change within the healthcare industry. In his current role at Plug and Play Health—the healthcare arm of one of the world’s most active venture capital firms and global innovation platforms—Alsaleh manages a vast ecosystem of startups, corporate partners, and institutional investors. Plug and Play is renowned for its role in accelerating early-stage companies, having been an early investor in tech giants like PayPal and Dropbox. Within the health vertical, the organization focuses on identifying and scaling digital health solutions, medical devices, and biotechnological advancements that address unmet clinical needs.
Prior to his leadership at Plug and Play, Mr. Alsaleh spent a significant portion of his career at Oracle Health (formerly Cerner Corporation), where he occupied several high-impact roles. Notably, he spearheaded the creation and implementation of Oracle’s health equity team. This initiative was designed to address social determinants of health (SDOH)—the non-medical factors such as socioeconomic status, education, and physical environment that influence health outcomes. By integrating these factors into healthcare IT and strategy, Alsaleh helped pave the way for more inclusive and accessible medical systems.
His influence at Oracle also extended to the philanthropic sector. As a member of the Oracle Charitable Foundation Clinical Decision Committee, he played a central role in the evaluation and distribution of more than $42 million in healthcare-related grants. This experience provided him with a nuanced understanding of how philanthropic capital can be leveraged to drive clinical progress, a skill set that aligns directly with CureSearch’s mission to fund high-impact research.
Regulatory Expertise and Global Advocacy
Beyond the private sector, Mr. Alsaleh has been a consistent presence in the regulatory and public policy spheres. His advisory work has touched on critical national and international initiatives, including collaborations with the Centers for Medicare & Medicaid Services (CMS) on quality reporting measures. During the height of the global pandemic, he contributed his expertise to the White House COVID-19 Taskforce, assisting in the coordination of large-scale responses to a global health crisis.
His international footprint is equally substantial. Mr. Alsaleh has collaborated with major global entities, including the World Bank Group and the World Health Organization (WHO), as well as the U.S. State Department. These experiences have allowed him to view healthcare challenges through a global lens, recognizing that the barriers to pediatric cancer treatment—such as regulatory hurdles and market fragmentation—are international issues requiring coordinated, cross-border solutions.
The Chronic Underfunding of Pediatric Oncology Research
The appointment of a venture capital and technology expert to the CureSearch board addresses a critical structural challenge in the fight against childhood cancer. While significant strides have been made in adult oncology, pediatric cancer research remains chronically underfunded and underrepresented in the broader pharmaceutical R&D pipeline.
According to data from the National Cancer Institute (NCI), while cancer is the leading cause of death by disease among children in the United States, only about 4% of federal funding for cancer research is specifically dedicated to pediatric cancers. This disparity is further exacerbated in the private sector. Traditional venture capital firms and pharmaceutical companies often view pediatric oncology as a "small market" compared to adult cancers like lung, breast, or prostate cancer. Consequently, the "Valley of Death"—the gap between initial laboratory discovery and the start of clinical trials—is particularly wide for pediatric drugs.
Since 1980, only a small fraction of the drugs approved by the FDA for cancer treatment were originally developed for children. Most pediatric treatments are "off-label" uses of adult medications, which may not be optimized for the unique biological and developmental needs of a growing child. CureSearch for Children’s Cancer seeks to disrupt this trend by funding research that has a clear path to clinical application, and Mr. Alsaleh’s expertise is expected to be a catalyst in this endeavor.
Strategic Objectives and Board Reactions
The leadership at CureSearch views Alsaleh’s appointment as a strategic move to integrate more entrepreneurial and investment-focused methodologies into their philanthropic model. By leveraging his network within the startup and venture capital communities, the organization aims to attract "non-traditional" investors and tech partners to the cause of pediatric oncology.
In a statement regarding his new role, Mr. Alsaleh highlighted the necessity of integrating pediatrics into the mainstream innovation ecosystem. "Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh said. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized the value of this multidisciplinary approach. "Osama brings a unique and highly valuable perspective to CureSearch," Brancazio stated. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
Chronology of Leadership and Organizational Evolution
The addition of Mr. Alsaleh follows a period of significant growth and strategic refinement for CureSearch. Over the past decade, the organization has shifted its focus from general research funding to a more targeted "catapult" model. This model prioritizes research projects that demonstrate high potential for commercialization and clinical impact, effectively acting as a bridge between academia and industry.
- 2010s: CureSearch begins focusing on the "Acceleration Initiative," targeting the most difficult-to-treat pediatric cancers.
- 2020-2022: The organization adapts to the challenges of the COVID-19 pandemic, maintaining research continuity despite global disruptions.
- 2023: CureSearch expands its focus on health equity, ensuring that advancements in pediatric oncology reach underserved populations.
- 2024: Osama Alsaleh is appointed to the Board, signaling a deepened commitment to venture capital partnerships and technological integration.
Broader Implications for the Pediatric Cancer Landscape
The inclusion of a leader from Plug and Play Health on the CureSearch board reflects a broader trend in the non-profit sector: the adoption of "venture philanthropy." This approach applies the principles of venture capital—such as rigorous due diligence, milestone-based funding, and active management—to charitable giving. For pediatric cancer, this means not just funding a study, but actively working to ensure that the study leads to a viable drug or therapy that can be manufactured and distributed.
Furthermore, Mr. Alsaleh’s background in health equity suggests that CureSearch will continue to prioritize accessibility. As new, highly specialized treatments like CAR-T cell therapy and personalized genomic medicine emerge, there is a growing risk of a "treatment gap" where only families with significant resources can access the latest innovations. Alsaleh’s previous work in shaping strategies for social determinants of health will be instrumental in ensuring that CureSearch-funded breakthroughs are accessible to all children, regardless of their socioeconomic background.
The integration of advanced technology—such as artificial intelligence in drug discovery and real-world evidence (RWE) in clinical trials—is another area where Alsaleh’s influence will likely be felt. By connecting CureSearch with the tech-driven startups in the Plug and Play ecosystem, the organization can explore how digital health tools can improve the efficiency of pediatric clinical trials, which often struggle with low patient enrollment due to the rarity of specific childhood cancers.
Conclusion: A Synergistic Path Forward
As CureSearch for Children’s Cancer continues its mission to end childhood cancer, the appointment of Osama Alsaleh represents a sophisticated understanding of the modern healthcare economy. To solve a problem as complex as pediatric cancer, the traditional boundaries between non-profit advocacy, government regulation, and private investment must be dissolved.
By bringing together Mr. Alsaleh’s expertise in venture capital and health technology with CureSearch’s deep roots in the scientific and patient advocacy communities, the organization is well-positioned to accelerate the next generation of therapies. The goal remains clear: to ensure that every child diagnosed with cancer has access to a treatment that is not only effective but specifically designed for their needs, ultimately leading to a future where childhood cancer is a curable condition for all.
